Comparison tool
Cagrilintide vs CagriSema side-by-side
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Comparison tool
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Selected (2/4)
Share this peptide comparison
| Property | Cagrilintide | CagriSema |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Also known as | AM833, NN9838, CagriSema (combination) | Semaglutide + Cagrilintide |
| FDA approved | No | No |
| Clinical status | Investigational phase 3 program, mainly through CagriSema; source reports an NDA submitted in Dec 2025 with FDA decision expected in Q4 2026.
| NDA submitted Dec 18, 2025; FDA decision expected Q4 2026.
|
| What to expect | Weight loss, appetite control, combination therapy | Maximum weight loss, combination therapy, obesity |
| How it works | Cagrilintide is described as a long-acting amylin analog with activity across the amylin and calcitonin receptor family. The source reports signaling through amylin receptor complexes, including receptors formed by calcitonin receptors with RAMP proteins. Reported downstream effects include central satiety signaling, delayed gastric emptying, and moderation of meal-related glucagon increases. Mechanistic animal data in the source emphasize AMY1R and AMY3R pathways involving hindbrain regions such as the area postrema, nucleus of the solitary tract, and parabrachial nucleus. The molecule is described as a modified pramlintide-like 37-amino-acid analog with a fatty-diacid modification intended to extend exposure to about one week. | CagriSema combines semaglutide, a GLP-1 receptor agonist, with cagrilintide, a long-acting amylin analog. The source links semaglutide to insulin response after meals, delayed gastric emptying and fullness signaling, while cagrilintide is described as acting through amylin-related satiety pathways in the brain. The proposed research rationale is that concurrent GLP-1 and amylin signaling may produce stronger appetite effects than either pathway alone. |
| Typical dosing | 2.4 mg weekly · Once weekly | Limited community data available · See research protocols |
| Research dosing | 2.4 mg weekly · Once weekly · Long-term / chronic use expected · Subcutaneous injection once weekly | Semaglutide 2.4 mg + cagrilintide 2.4 mg weekly · Weekly · Long-term use expected · Subcutaneous injection weekly |
| Typical duration | Long-term / chronic use expected | Long-term use expected |
| Administration | Subcutaneous injection once weekly | Subcutaneous injection weekly |
| Timing | Any consistent time weekly With or without food | - |
| Evidence level | Clinical Trials | Clinical Trials |
| Possible side effects |
+8 more
|
+4 more
|
| Research summary | The supplied source describes cagrilintide as having controlled human evidence, including a 2021 phase 2 dose-finding trial in which once-weekly 4.5 mg cagrilintide was associated with about 10.8% mean body-weight loss over 26 weeks, compared with roughly 3% for placebo and about 9% for liraglutide 3.0 mg. The source also highlights phase 3 REDEFINE development for CagriSema in obesity and type 2 diabetes, with weight-loss results reported in the low-20% range for the combination. Gastrointestinal tolerability issues, especially nausea and vomiting, are described as prominent. As presented by the source, cagrilintide remains investigational rather than an approved standalone therapy. | The supplied research summary describes two phase 3 REDEFINE studies. In REDEFINE 1, about 3,400 adults with overweight or obesity without diabetes were followed for 68 weeks; reported average body-weight change was about 20.4% with CagriSema, compared with 14.9% for semaglutide, 11.5% for cagrilintide and 3.0% for placebo. REDEFINE 2 enrolled adults with type 2 diabetes and is described as meeting endpoints for weight reduction and HbA1c improvement versus placebo. The source also notes that the approximately 20% result was below Novo Nordisk's 25% target, and that gastrointestinal events were the most common adverse effects. |
| References | ||
| Full profile | View Details | View Details |
Save this comparison
Keep this research set handy with a free PeptiGuide account.
Save this comparison - free accountTrack your peptide journey
Turn research into a private protocol log when you are ready.
Track your peptide journeyEducational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.